Aspects of the transport and delivery of antisense oligonucleotides

Current Opinion in Molecular Therapeutics

Volumn 2, Issue 3, 2000, Pages 297-303

  Juliano, Rudy L ^a   Yoo, Hoon ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Delivery; Oligonucleotide; Peptide; Transport; Uptake

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE;

BINDING AFFINITY; CELL MEMBRANE TRANSPORT; CELL METABOLISM; ENDOCYTOSIS; GENE TARGETING; HUMAN; NONHUMAN; PROTEIN TRANSPORT; REVIEW;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT, ACTIVE; CARRIER PROTEINS; DRUG DELIVERY SYSTEMS; HUMANS; LIPID BILAYERS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0033947612     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Akhtar S, Juliano RL: Cellular uptake and intracellular fate of antisense oligonucleotides. Trends Cell Biol (1992) 2:139-143.
2. Bennett CF: Antisense oligonucleotides: Is the glass half full or half empty? Biochem Pharmacol (1998) 55:9-19.
3. Stein CA, Cheng Y-C: Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science (1993) 261:1004-1012.
4. Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM: Binding, uptake and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest (1995) 95:1814-1823.
5. Shoji Y, Akhtar S, Periasamy A, Herman B, Juliano RL: Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages. Nucleic Acids Res (1991) 19:5543-5550.
6. Fisher TL, Terhorst T, Cao X, Wagner RW: Intracellular disposition and metabolism of fluorescently-labeled unmodified oligonucleotides microinjected into mammalian cells. Nucleic Acids Res (1993) 21:3857-3865.
7. Leonetti JP, Mechti N, Degols G, Gagnor C, Lebleu B: Intracellular distribution of micro-injected antisense oligonucleotides. Proc Natl Acad Sci USA (1991) 88:2702-2706.
8. Takakura Y, Oka Y, Hashida M: Cellular uptake properties of oligonucleotides in LLC-PK1 renal epithelial cells. Antisense Nucleic Acid Drug Dev (1998) 8:67-73.
9. Laktionov PP, Dazard JE, Vives E, Rykova EY, Piette J, Vlassov VV, Lebleu B: Characterization of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res (1999) 27:2315-2324.
10. Good L, Nielsen PE: Antisense inhibition of gone expression in bacteria by PNA targeted to mRNA. Nature Biotechnol (1998) 16:355-358.
11. Matteucci M: Structural modifications toward improved antisense oligonucleotides. Drug Des Discov (1996) 4:1-16.
12. Summerton J, Weller D: Morpholino antisense oligomers: Design, preparation, and properties. Antisense Nucleic Acid Drug Dev (1997) 7:187-195.
13. Akhtar S, Juliano RL: Permeation characteristics of antisense DNA oligonucleotide analogs across model membranes (liposomes). Nucleic Acids Res (1991) 19:5551-5559.
14. Hughes JA, Bennett CF, Cook PD, Guinosso CJ, Mirabelli CK, Juliano RL: Lipid membrane permeability of 2′-modified derivatives of phosphorothioate oligonucleotides. J Pharm Sci (1994) 83:597-600.
15. Wittung P, Kajanus J, Edwards K, Nielsen P, Norden B, Malmstrom BG: Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett (1995) 365:27-29.
16. Tyler BM, Jansen K, McCormick DJ, Douglas CL, Boules M, Stewart JA, Zhao L, Lacy B, Cusack B, Fauq A, Richelson E: Peptide nucleic acids targeted to the neurotensin receptor and administered ip cross the blood-brain barrier and specifically reduce gene expression. Proc Natl Acad Sci USA (1999) 96:7053-7058.
17. Jain MK (Ed): Introduction to Biological Membranes. J Wiley, NY, USA (1988).
18. Summerton J, Stein D, Huang SB, Matthews P, Weller D, Partridge M: Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev (1997) 7:63-70.
19. Schmajuk G, Sierakowska H, Kole R: Antisense oligonucleotides with different backbones. Modification of splicing pathways and efficacy of uptake. J Biol Chem (1999) 274:21783-21789.
20. Hanss B, Leal-Pinto E, Bruggeman LA, Copeland TD, Klotman PE: Identification and characterization of a cell membrane nucleic acid channel. Proc Natl Acad Sci USA (1998) 95:1921-1926.
21. Corrias S, Cheng YC: Interaction of human plasma membrane proteins and oligodeoxynucleotides. Biochem Pharmacol (1998) 55:1221-1227.
22. Benimetskaya L, Loike JD, Khaled Z, Loike G, Silverstein SC, Cao L, el Khoury J, Cai TQ, Stein CA: Mac-1 (CD11WCD18) is an oligodeoxynucleotide-binding protein. Nature Med (1997) 3:414-420.
23. Biessen EA, Vietsch H, Kuiper J, Bijsterbosch MK, Berkel TJ: Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol (1998) 53:262-269.
24. Steward A, Christian RA, Hamilton KO, Nicklin PL: Co- administration of polyanions with a phosphorothioate oligodeoxynucleotide (CGP 69846A): A role for the scavenger receptor in its in vivo disposition. Biochem Pharmacol (1998) 56:509-516.
25. Butler M, Crooke RM, Graham MJ, Lemonidis KM, Lougheed M, Murray SF, Witchell D, Steinbrecher U, Bennett CF: Phosphorothioate oligodeoxynucleotides distribute similarly in class A scavenger receptor knockout and wild- type mice. J Pharmacol Exp Ther (2000) 292:489-496.
26. Bachmann AS, Surovoy A, Jung G, Moelling K: Integrin receptor- targeted transfer peptides for efficient delivery of antisense oligodeoxynucleotides. J Mol Med (1998) 76:126-132.
27. Basu S, Wickstrom E: Synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellular uptake. Bioconjug Chem (1997) 8:481-488.
28. Politz JC, Browne ES, Wolf DE, Pederson T: Intranuclear diffusion and hybridization state of oligonucleotides measured by fluorescence correlation spectroscopy in living cells. Proc Natl Acad Sci USA (1998) 95:6043-6048.
29. Lukacs GL, Haggle P, Seksek O, Lechardeur D, Freedman N, Verkman AS: Size-dependent DNA mobility in cytoplasm and nucleus. J Biol Chem (2000) 275:1625-1629.
30. Lorenz P, Misteli T, Baker BF, Bennett CF, Spector DL: Nucleocytoplasmic shuttling: A novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res (2000) 28:582-592.
31. Branden LJ, Mohamed AJ, Smith CI: A peptide nucleic acid- nuclear localization signal fusion that mediates nuclear transport of DNA. Nature Biotechnol (1999) 17:784-787.
32. Shoeman RL, Hartig R, Huang Y, Grub S, Traub P: Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev (1997) 7:291-308.
33. Lorenz P, Baker BF, Bennett CF, Spector DL: Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol Biol Cell (1998) 9:1007-1023.
34. Felgner PL, Tsai YJ, Sukhu L, Wheeler CJ, Manthorpe M, Marshall J, Cheng SH: Improved cationic lipid formulations for in vivo gene therapy. Ann NY Acad Sci (1995) 772:126-139.
35. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem (1995) 270:18997-19007.
36. Gao X, Huang L: Cationic liposome-mediated gene transfer. Gene Ther (1995) 2:710-722.
37. Lewis JG, Lin K-Y, Kothavale A, Flanagan WM, Matteucci MD, DePrince RB, Mook RA, Hendren RW, Wagner RW: A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc Natl Acad Sci USA (1996) 93:3176-3181.
38. DeLong RK, Yoo H, Alahari SK, Fisher M, Short SM, Kang SH, Zirbes E, Kole R, Janout V, Regan SL, Juliano RL: Novel cationic amphiphiles as delivery agents for antisense oligonucleotides. Nucleic Acids Res (1999) 27:3334-3341.
39. DeLong R, Stephenson K, Loftus T, Fisher M, Alahari S, Nolting A, Juliano RL: Characterization of complexes of oligonucleotides with polyamidoamine starburst dendrimers and effects on intracellular delivery. J Pharm Sci (1997) 86:762-764.
40. Tang MX, Redemann CT, Szoka FC: In vitro gene delivery by degraded polyamidoamine dendrimers. Bioconjug Chem (1996) 7:703-714.
41. Yoo H, Sazani P, Juliano RL: PAMAM dendrimers as delivery agents for antisense oligonucleotides. Pharm Res (1999) 16:1799-1804.
42. Lindgren M, Hallbrink M, Prochiantz A, Langel U: Cell- penetrating peptides. Trends Pharm Sci (2000) 21:99-103.
43. Bongartz J-P, Aubertin A-M, Milhaud PG, Lebleu B: Improved biological activity of antisense oligonucleotides conjugated to a fusogenic peptide. Nucleic Acids Res (1994) 22:4681-4688.
44. Parente RA, Nir S, Szoka FCJ: Mechanism of leakage of phospholipid vesicle contents induced by the peptide GALA. Biochemistry (1990) 29:8720-8728.
45. Hughes JA, Aronsohn AI, Avrutskaya AV, Juliano RL: Evaluation of adjuvants that enhance the effectiveness of antisense oligonucleotides. Pharm Res (1996) 13:404-410.
46. Vives E, Brodin P, Lebleu B: A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem (1997) 272:16010-16017.
47. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J: Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA (1994) 91:664-668.
48. Kim DT, Mitchell DJ, Brockstedt DG, Fong L, Nolan GP, Fathman CG, Engleman EG, Rothbard JB: Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J Immunol (1997) 159:1666-1668.
49. Derossi D, Joliot AH, Chassaing G, Prochiantz A: The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem (1994) 269:10444-10450.
50. Troy CM, Stefanis L, Prochiantz A, Greene LA, Shelanski ML: The contrasting roles of ICE family proteases and interleukin-1b in apoptosis Induced by trophic factor withdrawal and by copper/zinc superoxide dismutase downregulation. Proc Natl Acad Sci USA (1996) 93:5635-5640.
51. Allinquant B, Hantraye P, Mailleux P, Moya K, Bouillot C, Prochiantz A: Downreguation of amyloid precursor protein inhibits neurite outgrowth in vitro. J Cell Biol (1995) 128:919-927.
52. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, Hokfelt T, Bartfai T, Langel U: Cell-penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nature Biotechnol (1998) 16:857-861.
53. Aldrian-Herrada G, Desarmenien MG, Orcel H, Boissin-Agasse L, Mery J, Brugidou J, Rabie A: A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res (1998) 26:4910-4916.
54. Astriab-Fisher A, Sergueev DS, Fisher M, Shaw BR, Juliano RL: Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. Biochem Pharmacol (2000) in press.
55. Elliott G, O'Hare P: Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell (1997) 88:223-233.
56. Phelan A, Elliott G, O'Hare P: Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nature Biotechnol (1998) 16:440-443.
57. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF: Killing HIV-infected cells by transaction with an HIV protease-activated caspase-3 protein. Nature Med (1999) 5:29-33.
58. Nagahara H, Vocero-Akbani AM, Snyder EL, Ho A, Latham DG, Lissy NA, Becker-Hapak M, Ezhevsky SA, Dowdy SF: Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nature Med (1998) 4:1449-1452.
59. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science (1999) 285:1569-1572.
60. Xoconostle-Cazares B, Xiang Y, Ruiz-Medrano R, Wang HL, Monzer J, Yoo BC, McFarland KC, Franceschi VR, Lucas WJ: Plant paralog to viral movement protein that potentiates transport of mRNA into the phloem. Science (1999) 283:94-98.
61. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A: Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem (1996) 271:18188-18193.
62. Morris MC, Chaloin L, Mery J, Heitz F, Divita G: A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res (1999) 27:3510-3517.
63. Pichon C, Roufai MB, Monsigny M, Midoux P: Histidylated oligolysines increase the transmembrane passage and the biological activity of antisense oligonucleotides. Nucleic Acids Res (2000) 28:504-512.
64. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, Dzau VJ: Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci USA (1999) 96:6411-6416.
65. Agrawal S, Iyer RP: Perspectives in antisense therapeutics. Pharmacol Ther (1997) 76:151-160.
66. Nolting A, DeLong RK, Fisher MH, Wickstrom E, Pollack GM, Juliano RL, Brouwer KL: Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver. Pharm Res (1997) 14:516-521.
67. Hughes JA, Avrutskaya AV, Brouwer KLR, Wickstrom E, Juliano RL: Radiolabeling of methylphosphonate and phosphorothioate oligonucleotides and evaluation of their transport in everted rat jejunum sacs. Pharm Res (1995) 12:817-824.
68. Graham MJ, Crooke ST, Monteith DK, Cooper SR, Lemonidis KM, Stecker KK, Martin MJ, Crooke RM: In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther (1998) 286:447-458.
69. Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Yan J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R: Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration. Biochem Pharmacol (1995) 50:571-576.
70. Nicklin PL, Bayley D, Giddings J, Craig SJ, Cummins LL, Hastewell JG, Phillips JA: Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes. Pharm Res (1998) 15:583-591.
71. Wang H, Cai Q, Zeng X, Yu D, Agrawal S, Zhang R: Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIα subunit of protein kinase A after oral administration. Proc Natl Acad Sci USA (1999) 96:13989-13994.
72. Liu DZ, LeCluyse EL, Thakker DR: Dodecylphosphocholine- mediated enhancement of paracellular permeability and cytotoxicity in Caco-2 cell monolayers. J Pharm Sci (1999) 88:1161-1168.